iVexSol
Ken Locke currently serves as Vice President, Manufacturing and Supply Chain at Carisma Therapeutics. Prior to joining Carisma, Ken served as Global Head of Cell Therapy External Manufacturing and Strategic Sourcing at Bristol Myers Squibb (formerly Celgene/Juno Therapeutics) where he was responsible for all external manufacturing operations for plasmid, viral vector and cell processing. Prior to BMS, Ken was Executive Director at Novartis supporting global materials and services sourcing for all Technical R&D as well as Cell and Gene Therapies. He has more than 25 years of pharmaceutical and biotechnology experience, including discovery, laboratory automation, sourcing/contracting strategy, supply chain and manufacturing.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
iVexSol
As Lentiviral vectors have transformed medicine with their safety and efficacy, they have created a demand for production that far exceeds current capacity. Traditional manufacturing systems have seen long wait times and critical raw material shortages cause delays in development and deployment of these life-altering therapies. Our Intelligent Vector Solutions(TM) can be used to manufacture ANY LENTI, ANY SCALE(TM) to provide our clients an END TO END solution, speeding their development and securing their supply chain.